Mendo Akdag: | Thank you, Bruce. Welcome everyone and thank you for joining us. Today we will review the highlights of our financial results. We will compare our third fiscal quarter ended on December 31, 2019 to last year's quarter ended on December 31, 2018. |
| For the third fiscal quarter ended on December 31, 2019, our sales were relatively flat at $59.9 million compared to $60.1 million for the same period the prior year. The average order value for the quarter was approximately $85 compared to $84 for the same quarter the prior year. For the third fiscal quarter, net income was $6.8 million, or $0.34 diluted per share, compared to $7.8 million, or $0.38 diluted per share, for the same quarter the prior year, a decrease to diluted earnings per share of 10%. The decrease to net income for the quarter was mainly due to lower gross profit margins. Net income margins for the quarter sequentially improved by 180 basis points compared to the September quarter, and 470 basis points compared to the June quarter. Reorder sales increased by 1.0% to $53.8 million for the quarter compared to reorder sales of $53.3 million for the same quarter of the prior year. New order sales decreased by 9.9% to $6.1 million for the quarter compared to $6.8 million for the same period the prior year. Increased online competition negatively impacted our new order sales. We acquired approximately 76,000 new customers in our third fiscal quarter compared to 81,000 for the same period the prior year. The seasonality in our business is due to the proportion of flea, tick, and heartworm medications in our product mix. Spring and summer are considered peak seasons, with fall and winter being the off seasons. For the third fiscal quarter, our gross profit as a percent of sales was 29.5% compared to 32.3% for the same period a year ago. Manufacturers’ minimum advertised price policies are bringing a general pricing discipline into the market, and as a result our gross profit margins for the quarter improved sequentially by 90 basis points compared to the September quarter and 220 basis points compared to the June quarter. |